New clues to early development of schizophrenia

Schizophrenia is a severe neuropsychiatric disease that remains poorly understood and treated. Schizophrenia onset is typically in adolescence or early adulthood, but its underlying causes are thought to involve neurodevelopmental abnormalities. Because human prenatal and postnatal brain tissue is exceedingly difficult to procure and therefore study, researchers have had limited opportunities to identify early disease mechanisms, especially during the critical prenatal period. Now, a pair of studies that appear in Biological Psychiatry 新しいタブ／ウィンドウで開く, published by Elsevier, use new technology to study schizophrenia in models of early human brain development.  

The first study 新しいタブ／ウィンドウで開く used a unique approach involving three-dimensional brain organoids, which are known to recapitulate fetal brain development. The researchers, led by first author Ibrahim A. Akkouh, PhD, and senior author Srdjan Djurovic, PhD, both at Oslo University Hospital, collected skin cells from 14 patients with schizophrenia and 14 healthy controls and generated induced pluripotent stem cells (iPSCs), which they then manipulated to develop into brain-like cortical spheroids.   

The organoids grown from patients and controls differed in their expression of thousands of genes – in line with the finding that the genetic influences on schizophrenia are many and very small. However, among the genes, those associated with neuronal axons stood out as a group.  

Dr. Akkouh explained, “We identified persistent axonal dysregulation as an early contribution to disease risk.”

Importantly, the researchers assessed organoid maturation at several time points, which enabled them to establish the persistent nature of the disturbances throughout development. 

Dr. Akkouh added, “Our findings provide novel and hitherto inaccessible insights into the molecular basis of schizophrenia during early brain development.”

In the second study 新しいタブ／ウィンドウで開く, researchers led by Roy H. Perlis, PhD, at Harvard Medical School, focused on a particular genetic risk locus. The schizophrenia risk locus 15q11.2, a particular chromosomal region containing four genes, has a penetrance of over 10%, translating to a doubling of risk for schizophrenia among people carrying an unusual copy number of this genetic region. One gene in the locus, CYFIP1, has been associated with synaptic function in neurons and confers increased risk for neurodevelopmental disorders including schizophrenia and autism.  

CYFIP1 is highly expressed in microglia, the brain’s own immune cells, but its function there is unknown. Microglia are known to carry out synaptic pruning, in which they “eat” excess synaptic structures, a process critical to healthy brain development.   

Dr. Perlis and colleagues collected blood cells from healthy volunteers and isolated iPSCs, which they then manipulated to differentiate into microglia-like cells. The researchers then used CRISPR technology to remove functional CYFIP1 from the cells.  

Dr. Perlis said of the work, “Our findings suggest that changes in the behavior and function of microglia due to aberrant CYFIP1 function, such as through coding or copy number variants, could affect microglial processes such as synaptic pruning, homeostatic surveillance, and neuronal maintenance, which are critical for proper brain development and function. This could contribute to CYFIP1-related neurodevelopmental and psychiatric disorders resulting in part from microglia dysfunction. Among the specific disorders linked to variation in CYFIP1 are both autism and schizophrenia.”

John Krystal, MD, Editor of Biological Psychiatry, commented, “The biology of schizophrenia is very complex and yet two themes represented by these two studies seem to be very important: the increased rate of elimination of glutamatergic synapses during development, and disturbances in the signaling properties of these glutamate synapses. These two disturbances could perturb circuit function in ways that are critical to development of symptoms and cognitive impairments associated with schizophrenia.”

Dr. Perlis added, “More broadly, our findings highlight the importance of looking beyond neurons to understand risk genes. While finding risk loci may be the first step in understanding the role of genes in brain diseases, it’s only a first step; figuring out the relevant cell type, and what those genes are doing, is absolutely critical in moving from association to – we hope – actual treatments.”

---

Notes for editors 

The first article is "Longitudinal Transcriptomic Analysis of Human Cortical Spheroids Identifies Axonal Dysregulation in the Prenatal Brain as a Mediator of Genetic Risk for Schizophrenia," by Ibrahim Akkouh, Thor Ueland, Attila Szabo, Timothy Hughes, Olav B. Smeland, Ole A. Andreassen, Jordi Requena Osete, Srdjan Djurovic (https://doi.org/10.1016/j.biopsych.2023.08.017 新しいタブ／ウィンドウで開く). It appears as an Article in Press in Biological Psychiatry 新しいタブ／ウィンドウで開く, published by Elsevier. 

The article is openly available at https://www.biologicalpsychiatryjournal.com/article/S0006-3223(23)01529-9/fulltext 新しいタブ／ウィンドウで開く.   

Copies of this paper are also available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected] 新しいタブ／ウィンドウで開く. Journalists wishing to interview the authors may contact ​Srdjan Djurovic​, PhD, at [email protected] 新しいタブ／ウィンドウで開く. 

The second article is "Loss of Function in the Neurodevelopmental Disease and Schizophrenia-Associated Gene CYFIP1 in Human Microglia-like Cells Supports a Functional Role in Synaptic Engulfment," by Steven D. Sheridan, Joy E. Horng, Hana Yeh, Liam McCrea, Jennifer Wang, Ting Fu, Roy H. Perlis (https://doi.org/10.1016/j.biopsych.2023.07.022 新しいタブ／ウィンドウで開く). It appears as an Article in Press in Biological Psychiatry 新しいタブ／ウィンドウで開く, published by Elsevier.  

Copies of this paper are available to credentialed journalists upon request; please contact ​Rhiannon Bugno​ at [email protected] 新しいタブ／ウィンドウで開く. Journalists wishing to interview the authors may contact Roy H. Perlis, PhD, at +1 647-643-3080 or [email protected] 新しいタブ／ウィンドウで開く. 

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.   

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here 新しいタブ／ウィンドウで開く. 

---

Notes for editors

About Biological Psychiatry 

Biological Psychiatry 新しいタブ／ウィンドウで開く is the official journal of the Society of Biological Psychiatry 新しいタブ／ウィンドウで開く, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.  

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.  

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 12^th out of 155 Psychiatry titles and 17^th out of 272 Neurosciences titles in the Journal Citation Reports^TM published by Clarivate Analytics. The 2022 Impact Factor score for Biological Psychiatry is 10.6. www.sobp.org/journal 新しいタブ／ウィンドウで開く

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。